Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have earned a consensus recommendation of “Moderate Buy” from the eleven research firms that are covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $81.6667.

Several analysts have commented on the stock. The Goldman Sachs Group boosted their price target on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 7th. Morgan Stanley boosted their target price on Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 7th. Chardan Capital increased their price target on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Bank of America raised their price target on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $110.00 price objective (up from $100.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, January 13th.

Trending Headlines about Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Early reports show a “strong start” to REDEMPLO commercialization, which supports near-term revenue traction and helps explain buying interest despite mixed guidance from some analysts. ARWR: Strong Start for REDEMPLO Commercialization
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $100 price target while raising several multi‑year estimates (notably FY2028–FY2030 upside and some quarterly lifts), signaling confidence in Arrowhead’s longer-term pipeline and commercialization prospects — a bullish catalyst for investors focused on growth potential. HC Wainwright Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
• Neutral Sentiment: Short‑interest data reported zero shares and NaN changes for mid‑February (likely a reporting/data anomaly). Current short‑interest ratio is shown as 0.0 days — this item appears to have no actionable impact on supply/demand given the inconsistent figures.
• Negative Sentiment: Zacks Research cut multiple near‑term and longer‑term EPS forecasts (Q2–Q4 2026 and FY2026–FY2028), lowering Q2–Q4 2026 quarter estimates and materially reducing FY2026 and FY2027 forecasts. Those downward revisions add pressure to near‑term earnings expectations and may weigh on sentiment for value/earnings‑driven traders.

Insider Buying and Selling

In related news, CEO Christopher Richard Anzalone sold 13,187 shares of the company’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $66.10, for a total transaction of $871,660.70. Following the sale, the chief executive officer owned 3,792,739 shares of the company’s stock, valued at $250,700,047.90. This represents a 0.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Patrick O’brien sold 49,493 shares of Arrowhead Pharmaceuticals stock in a transaction on Monday, January 5th. The stock was sold at an average price of $63.11, for a total transaction of $3,123,503.23. Following the completion of the transaction, the chief operating officer directly owned 474,908 shares of the company’s stock, valued at $29,971,443.88. The trade was a 9.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 510,836 shares of company stock valued at $33,603,060 in the last three months. Corporate insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Marex Group plc purchased a new position in Arrowhead Pharmaceuticals during the 2nd quarter worth $576,000. Nordea Investment Management AB grew its position in shares of Arrowhead Pharmaceuticals by 74.5% during the 3rd quarter. Nordea Investment Management AB now owns 372,282 shares of the biotechnology company’s stock worth $12,661,000 after buying an additional 158,937 shares in the last quarter. Marshall Wace LLP grew its position in shares of Arrowhead Pharmaceuticals by 3,507.8% during the 2nd quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock worth $34,065,000 after buying an additional 2,096,238 shares in the last quarter. HBK Sorce Advisory LLC purchased a new position in shares of Arrowhead Pharmaceuticals during the third quarter valued at $2,823,000. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the third quarter valued at about $287,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Trading Up 2.3%

Shares of ARWR opened at $63.82 on Friday. The firm has a market cap of $8.94 billion, a P/E ratio of 41.71 and a beta of 1.21. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.38 and a quick ratio of 3.38. Arrowhead Pharmaceuticals has a 1 year low of $9.57 and a 1 year high of $76.76. The company has a 50 day simple moving average of $67.03 and a two-hundred day simple moving average of $45.26.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). The company had revenue of $264.03 million for the quarter, compared to the consensus estimate of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.Arrowhead Pharmaceuticals’s revenue was up 10461.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.39) EPS. On average, equities analysts expect that Arrowhead Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.